Average number of school days missed annually ranged from 10.9 (severe AD) to 3.4 (mild AD; P<0.01). Likewise, 87% of caregivers of an adolescent with severe AD reported missing at least one workday in the past four weeks, versus 66.3% for moderate AD and 44.8% for mild AD.
"When comparing the results from the study with previously published data in adults,3" writes Weidinger et al., "the disease burden associated with AD appears to be higher in adolescents than in adults, implying that there is an even greater unmet therapeutic need in the management of adolescents with moderate-to-severe AD."
These results emphasize that the adolescent population would potentially benefit from tighter disease control, and potentially stepping up therapy, Dr. Silverberg says.
"The pediatric population has often been neglected from a therapeutic standpoint because pediatricians and pediatric dermatologists are often a little more hesitant about using some of the oral systemic immunosuppressants because of their toxicity and side-effect profile,” he says, “We are starting to see the development of newer, potentially more potent and safer therapeutics for the pediatric population. The growing recognition of the burden of AD in adolescents and hopefully better treatment options will allow for this patient population to be treated more appropriately and ultimately to achieve better long-term control of their disease."
Dr. Silverberg has received honoraria as a speaker/consultant for Galderma, Abbvie, AnaptysBio, Asana BioSciences, Arena, Boehringer-Ingelheim, Dermavant, Eli Lilly, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Novartis, Pfizer, and Regeneron-Sanofi and has received grants as an investigator from Galderma and GlaxoSmithKline.
1. Silverberg JI, Barbarot S, Simpson EL, et al. Epidemiology of atopic dermatitis in the adolescent population: a cross-sectional study in the United States and Europe. Poster P1458. European Academy of Dermatology and Venereology Congress; October 9-13, 2019. Madrid, Spain.
2. Weidinger S, Simpson EL, Silverberg JI, et al. The patient-reported disease burden in adolescents with atopic dermatitis: a cross-sectional study in the United States and Europe. Poster P1459. European Academy of Dermatology and Venereology Congress; October 9-13, 2019. Madrid, Spain.
3. Girolomoni G, Gadkari A, Auziere S, et al. Characterizing the patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study from clinical practices in Europe and Canada. Poster P0253. European Academy of Dermatology and Venereology Congress; September 12-16, 2018. Paris, France.